Why the study?
Does oral digoxin improve outcomes in high-risk chronic heart failure patients with NYHA class III-IV, LVEF <25%, or CTR >55%?
Does oral digoxin improve outcomes in high-risk chronic heart failure patients with NYHA class III-IV, LVEF <25%, or CTR >55%?
Oral digoxin improves outcomes in a high-risk subgroup of chronic heart failure patients with severe symptoms, low ejection fraction, or cardiomegaly.
Supports digoxin in high-risk chronic HF; extends RCT evidence to NYHA III-IV with LVEF <25% or CTR >55%.
Digoxin improves outcomes in chronic HF patients with NYHA class III-IV, LVEF <25%, or CTR >55%, and should be considered in these patients.
No takes yet. Share an insight, caveat, or question.
Gheorghiade et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: